InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.840
-0.160 (-8.00%)
At close: Jun 5, 2026, 4:00 PM EDT
1.870
+0.030 (1.63%)
After-hours: Jun 5, 2026, 5:22 PM EDT
InflaRx Revenue
InflaRx had revenue of 29.33K EUR in the twelve months ending March 31, 2026, down -77.39% year-over-year. In the year 2025, InflaRx had annual revenue of 29.33K, down -82.31%.
Revenue (ttm)
29.33K EUR
Revenue Growth
-77.39%
P/S Ratio
8,013.80
Revenue / Employee
451 EUR
Employees
65
Market Cap
271.02M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.33K | -136.46K | -82.31% |
| Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
| Dec 31, 2023 | 63.09K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Zentalis Pharmaceuticals | 26.87M |
| Lineage Cell Therapeutics | 14.78M |
| Surrozen | 7.49M |
| Armata Pharmaceuticals | 5.20M |
| Lyell Immunopharma | 31.00K |
| Inhibikase Therapeutics | 1.00 |
IFRX News
- 24 days ago - InflaRx upgraded to Strong Buy from Outperform at Raymond James - TheFly
- 26 days ago - InflaRx price target raised to $8 from $6 at H.C. Wainwright - TheFly
- 4 weeks ago - InflaRx Transcript: Investor update - Transcripts
- 4 weeks ago - InflaRx Press release: Investor update - Filings
- 4 weeks ago - InflaRx Slides: Investor update - Filings
- 4 weeks ago - InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - GlobeNewsWire
- 4 weeks ago - InflaRx to develop izicopan in AAV - TheFly
- 4 weeks ago - InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares - GlobeNewsWire